# Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

> **NCT05983198** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 225Ac-PSMA-R2
- **RADIATION:** 68Ga-PSMA-R2
- **RADIATION:** 68Ga-PSMA-11

## Key facts

- **NCT ID:** NCT05983198
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-07
- **Primary completion:** 2026-11-19
- **Final completion:** 2029-11-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983198, "Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05983198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*